Robbins LLP Files Class Action Lawsuit Against Baxter International for Investor Misleading Claims

Class Action Lawsuit Filed Against Baxter International, Inc.

On July 31, 2025, it was reported that Robbins LLP has initiated a class action lawsuit against Baxter International, Inc. This legal action has been taken on behalf of investors who bought or acquired common stock of Baxter between February 23, 2022, and July 30, 2025, amid allegations that the company misrepresented crucial safety information relating to one of its medical devices, the Novum LVP.

Overview of Baxter International and the Novum LVP

Baxter International, Inc. is a globally recognized enterprise engaged in the development, manufacturing, and marketing of medical products that are widely utilized in hospitals and various healthcare settings. One of their key products, the Novum Large Volume Pump (LVP), is designed for the controlled delivery of intravenous (IV) fluids, which are essential for administering medications, blood products, and nutrients to patients.

However, reports surfaced indicating that Baxter was aware of numerous systemic malfunctions associated with the Novum LVP, which resulted in severe issues like underinfusion, overinfusion, or, in some cases, the complete failure to deliver needed fluids to patients. Such malfunctions posed significant risks, including severe injuries and even fatalities among patients.

The Allegations Against Baxter

The class action highlights several critical failures on the part of Baxter:

1. Failure to Disclose Safety Concerns: The company did not adequately inform investors about the existence of systemic defects in the Novum LVP that led to significant malfunctions.
2. Inadequate Remedial Actions: Despite receiving multiple notifications regarding device failures and associated injuries, Baxter's attempts to rectify these issues through customer alerts were deemed insufficient.
3. Material Misrepresentation: Baxter provided statements regarding the safety, effectiveness, and market rollout of the Novum LVPs that were found to be materially false or misleading.
4. Market Reaction: The situation worsened when, on July 31, 2025, Baxter announced a temporary suspension of all new sales of the Novum LVP. This announcement directly led to a 22.4% drop in the stock price, closing at just $21.76 per share.

Implications for Investors

Robbins LLP is urging all shareholders who are interested in acting as lead plaintiffs in the case to submit their documentation by December 15, 2025. The lead plaintiff will represent the collective interests of all affected class members while pursuing the case.

Importantly, investors have options: participation in the lawsuit is not a requirement to qualify for potential recoveries. Shareholders can choose to remain absent from the case while still being eligible for any recovery resulting from the litigation.

Robbins LLP operates on a contingency fee structure, ensuring that shareholders will incur no upfront legal fees or expenses.

About Robbins LLP

Established in 2002, Robbins LLP has gained recognition as a leader in shareholder rights litigation. The firm is committed to aiding shareholders in their recovery efforts, enhancing corporate governance practices, and holding company leaders accountable for their wrongdoings. As part of their ongoing efforts, they encourage individuals to sign up for their Stock Watch service, which notifies subscribers of any developments related to Baxter and other corporations regarding shareholder rights litigation.

The implications of this lawsuit could be far-reaching for Baxter International and its investors. Stakeholders should remain vigilant about developments related to the case and consider their options carefully as they navigate these challenging waters.